Senate Resolution 74—Declaring That Achieving the Primary Goal of the National Plan to Address Alzheimer’s Disease of the Department of Health and Human Services to Prevent and Effectively Treat…by Senator Susan M. Collins
Posted on 2015-02-12
COLLINS (for herself, Ms. Klobuchar, Ms. Mikulski, Mr. Warner,
Ms. Stabenow, Mr. Durbin, Mr. Markey, and Mr. Whitehouse) submitted the
following resolution; which was referred to the Committee on Health,
Education, Labor, and Pensions:
S. Res. 74
Whereas the number of individuals in the United States with
Alzheimer's disease and related dementias (referred to in
this preamble as ``Alzheimer's'') is as high as 5,200,000,
which is more than double the number in 1980;
Whereas based on the trajectory of Alzheimer's, as many as
16,000,000 individuals in the United States may have
Alzheimer's by 2050;
Whereas the increasing prevalence of Alzheimer's and other
dementias is a global health crisis that afflicts an
estimated 44,000,000 individuals worldwide as of December,
2013 and may afflict over 135,000,000 individuals by 2050;
Whereas Alzheimer's is a leading cause of death in the
United States with new data indicating that more than 500,000
deaths each year are attributable to the disease;
Whereas Alzheimer's is the only disease among the top 10
causes of death in the United States without an effective
means of prevention, treatment, or cure;
Whereas Alzheimer's places an enormous financial strain on
families, the health care system, and State and Federal
Whereas the Medicare program under title XVIII of the
Social Security Act (42 U.S.C. 1395 et seq.) and the Medicaid
program under title XIX of the Social Security Act (42 U.S.C.
1396 et seq.) are estimated to bear more than two-thirds of
the total costs of this care in 2015;
Whereas a RAND Corporation study published in 2013 and
commissioned by the National Institute on Aging found that
Alzheimer's is the costliest disease in the United States,
costing more than cancer and heart disease;
Whereas in 2013, an estimated 15,500,000 family members and
friends of individuals with Alzheimer's provided those
individuals with 17,700,000,000 hours of unpaid care, an
amount valued at more than $220,000,000;
Whereas Alzheimer's disease has a disproportionate impact
on many populations including women, African Americans, and
Whereas the global cost of Alzheimer's exceeds
$600,000,000,000 each year, an amount equal to approximately
1 percent of the world's gross domestic product;
Whereas in December 2013, the G-8 nations met and adopted a
political declaration supporting the goal of a cure or
disease-modifying therapy for dementia by 2025 as well as
collectively and significantly increasing resources committed
to dementia research;
Whereas Alzheimer's takes an emotional and physical toll on
caregivers that results in a higher incidence of chronic
conditions, such as heart disease, cancer, and depression
Whereas the National Plan to Address Alzheimer's Disease of
the Department of Health and Human Services enables family
caregivers of individuals with Alzheimer's to provide care
while maintaining personal health and well-being;
Whereas the National Plan to Address Alzheimer's Disease
supports informal caregivers by--
(1) identifying the support needs of caregivers;
(2) developing and disseminating modes for intervention;
(3) providing information that caregivers need,
particularly in crisis situations; and
(4) assisting caregivers in maintaining personal health and
Whereas a strong and sustained research effort is the best
tool to slow the progression and ultimately prevent the onset
Whereas while the cost to the Medicare and Medicaid
programs of caring for Alzheimer's patients is estimated to
be $153,000,000,000 in 2015, the United States, through the
National Institutes of Health, will spend about $586,000,000
on Alzheimer's research in 2015;
Whereas the Chairman of the Advisory Council on Alzheimer's
Research, Care, and Services created by the National
Alzheimer's Project Act (42 U.S.C. 11225) has testified
before Congress that the United States must devote at least
$2,000,000,000 each year to Alzheimer's research to reach the
goal of preventing and effectively treating Alzheimer's by
Whereas the public members of the Advisory Council on
Alzheimer's Research, Care, and Services unanimously agree
with the testimony of the Chairman regarding the amount of
money required to reach the goal for 2025: Now, therefore, be
Resolved, That the Senate--
(1) is committed to strengthening the quality of care and
expanding support for individuals with Alzheimer's disease
and related dementias (referred to in this resolution as
``Alzheimer's'') and family caregivers of individuals with
(2) declares that achieving the primary goal of the
National Plan to Address Alzheimer's Disease to prevent and
effectively treat Alzheimer's by 2025 is an urgent national
(3) recognizes that bold action and considerable increases
in funding are necessary to meet that goal;
(4) encourages greater collaboration between the United
States and other global governments, particularly the G-7
nations, to advance a global Alzheimer's and dementia
(5) supports innovative public-private partnership and the
pursuit of innovative financing tools, incentives and other
mechanisms to accelerate the pursuit of disease-modifying
(6) strives to--
(A) double the amount of funding the United States spends
on Alzheimer's research in fiscal year 2016; and
(B) develop a plan for fiscal years 2017 through 2020 to
meet the target of the Advisory Council on Alzheimer's
and Services for the United States to spend $2,000,000,000
each year on Alzheimer's research.
Ms. COLLINS. Mr. President, Alzheimer's is a terrible disease that takes a tremendous personal and economic toll on the individual, the family, and society. In addition to the human suffering it causes, Alzheimer's costs the United States an estimated $226 billion a year, including $153 billion from the Medicare and Medicaid Programs. These costs will only skyrocket as the baby boom generation ages. Already our Nation's costliest disease, Alzheimer's is projected to cost more than $1.1 trillion if nothing is done to change its current trajectory. It is now estimated that nearly one in two of the baby boomers reaching age 85 will develop Alzheimer's. As a consequence, chances are that members of the baby boom generation will either be spending their golden years suffering with Alzheimer's or caring for someone who has it. In many ways Alzheimer's has become the defining disease of this generation.
If we are to prevent Alzheimer's from becoming the defining disease of the next generation, it is imperative that we dramatically increase our investment in Alzheimer's research. At a time when the United States is spending some $226 billion a year caring for Alzheimer's patients, we are spending less than three-tenths of 1 percent of that amount--under $600 million a year--on research. This makes no sense. We currently spend $4.5 billion a year for cancer research, $3 billion a year for research on HIV-AIDS, and $2 billion for cardiovascular research--all investments that have paid dividends.
Surely we can do more for Alzheimer's given the tremendous human and economic price of this devastating disease. Investments in research for other diseases have yielded tremendous results. We see that with cancer, with HIV/AIDS. Patients have access to new treatments, and death rates for some of these diseases are decreasing. At the same time, mortality due to Alzheimer's is escalating.
Alzheimer's is one of our Nation's leading causes of death, with recent data revealing that each year more than 500,000 deaths are attributable to Alzheimer's and other dementia, 6 times the amount previously estimated. Moreover, Alzheimer's is the only one of our Nation's top 10 deadliest diseases without an effective means of prevention, treatment or a cure.
Fortunately there is promising research that holds hope for Alzheimer's patients and their families. The research community is poised to make important advances through clinical trials and by investigating new therapeutic targets, but adequate funding is critical to achieve this promise. The National Plan to Address Alzheimer's Disease was authorized by the bipartisan National Alzheimer's Act, which I coauthored with then-Senator Evan Bayh.
The national plan has as its primary goal to prevent and effectively treat Alzheimer's disease by the year 2025. The chairman of the advisory council that was created by the act, Dr. Ronald Petersen of the Mayo Clinic, has testified before Congress that the United States should be devoting $2 billion a year at a minimum to Alzheimer's research in order to reach that goal.
A dramatic increase in funding for Alzheimer's research will not just save lives, it will also save money. According to a report issued by the Alzheimer's Association last year, a Federal investment of $2 billion a year between now and the year 2025, as recommended by the experts on the Alzheimer's Advisory Council and the scientific community more broadly, would be recouped within the first 3 years after a treatment delaying the onset of Alzheimer's by just 5 years becomes available.
I am therefore pleased to be introducing today, with my colleagues Senators Klobuchar, Mikulski, Warner, Durbin, and Stabenow, a resolution declaring that the goal of preventing and effectively treating Alzheimer's is an urgent national priority. In recognition of the fact that bold action and considerable increases in funding are necessary to meet that goal, our resolution states that the Senate will strive to double the amount of funding the United States spends on Alzheimer's research in fiscal year 2016 and that we will develop a plan to meet the target of $2 billion over the next 5 years.
Our bill is supported by a number of organizations including the Alzheimer's Association, UsAgainstAlzheimer's, the Leaders Engaged on Alzheimer's Disease--or the LEAD Coalition--and the Alzheimer's Foundation of America.
I ask unanimous consent that the letters from these organizations be printed in the Record.
There being no objection, the material was ordered to be printed in the Record, as follows: LEAD--Leaders Engaged on Alzheimer's Disease, February 11, 2015.
Hon. Susan Collins, Chairman, Special Committee on Aging, U.S. Senate, Washington, DC.
Dear Chairman Collins: As executive director of Leaders Engaged on Alzheimer's Disease (the LEAD Coalition), I write to thank you for your inspirational leadership in reintroducing the Senate resolution to strengthen care and support, encourage greater international collaboration, incentivize private sector research, double federal investments in Alzheimer's disease and related dementias research in FY 2016, and bring annual federal investments to at least $2 billion by 2020. Your resolution is an important next step toward each of these vital goals and the LEAD Coalition will continue to work arm-in-arm with you and your colleagues to realize the resolution's promise.
There are few more compelling or complex issues to confront our aging society now and over the coming decades than Alzheimer's disease and related dementias (including vascular, Lewy body or frontotemporal dementia). Its place as a national priority was made clear by the effort you led resulting in unanimous congressional passage of the National Alzheimer's Project Act. That law directed creation of the National Plan to Address Alzheimer's Disease and, as you know, the National Plan's goal number one is to prevent and effectively treat Alzheimer's disease and related dementias by 2025.
In fact, as your resolution highlights, Alzheimer's disease and related dementias are an urgent national priority that impose enormous costs to our nation's health and prosperity, costs that are skyrocketing. Today, more than five million Americans have dementia at an annual cost to our economy exceeding $200 billion. Alzheimer's disease contributes to the deaths of approximately 500,000 Americans each year, making it the third leading cause of death in the United States. If the current trajectory of the disease persists, between 13 million and 16 million Americans will have dementia in 2050 and total costs of care are projected to exceed (inflation adjusted 2014 dollars) $1 trillion annually. The federal government, through Medicare and Medicaid payments, shoulders an estimated 70 percent of all such direct care costs.
Globally, the stakes of American scientific leadership are higher still. Today, 44 million people have dementia with annual costs exceeding $600 billion or about one percent of the world's GDP. If the current trajectory of the disease persists, upwards of 135 million persons worldwide will have dementia in 2050. American scientific leadership is nowhere more urgent than in Alzheimer's disease and related dementias.
Congress, the President and NIH Director Dr. Francis Collins have overcome enormous obstacles to increase funding and prioritization of Alzheimer's disease and related dementias research over the past several years. The National Institute an Aging (NIA) and other NIH institutes--such as the National Institute of Neurological Disorders and Stroke, the National Institute of Biomedical Imaging and Bioengineering, the National Institute of Mental Health and the National Institute of Child Health and Human Development--are supporting a number of promising research projects to: understand the genetic risk factors, address the disproportionate impact on women, African Americans, Hispanics, and persons with intellectual disabilities; and pursue cutting-edge but costly and time consuming trials aimed at preventing or substantially slowing disease progression by administering treatments much earlier in the disease process. These resources of time, talent and treasure are precious and indefensibly scarce. We owe it to the taxpayers, to the research community and--most of all--to people living with, or at risk of, Alzheimer's disease and related dementias to provide adequate and necessary resources proportionate to the disease burden, unmet medical need, and our nation's ethical and moral compass.
The broad, diverse, and unified Alzheimer's disease and related dementias community--working together as the LEAD Coalition--deeply admires and appreciates your remarkable leadership on this and so many other issues of vital importance to our nation's cognitive health, economic well- being, and global scientific leadership. We look forward to working with you for passage of the resolution and subsequent congressional action on each of its goals.
Sincerely, Ian Kremer, Esq., Executive Director, LEAD Coalition.
[[Page S1005]] ____ USAgainstAlzheimers, February 10, 2015.
Hon. Susan Collins, Chairman, Special Committee on Aging, U.S. Senate, Washington, DC.
Dear Chairman Collins: On behalf of USAgainstAlzheimers, the national movement committed to mobilizing the nation around the goal of stopping Alzheimer's by 2020, I am writing to applaud you for recognizing the mounting threat of Alzheimer's and dementia and for leading the call for the level of public resources that are necessary to stop this disease before it destroys our nation's health and finances.
As you are well aware from your extensive history of leadership against Alzheimer's and dementia, more than five million Americans are currently suffering from this disease, and millions more are impacted as family members and caregivers. Economic estimates suggest that Alzheimer's disease costs the nation upwards of $200 billion each year, with about 70 percent of costs shouldered by Medicare and Medicaid. Direct care costs of Alzheimer's have been found to be larger than similar costs of cancer and heart disease, and a groundbreaking 2014 study from Rush University indicates that more than 500,000 deaths each year are attributable to Alzheimer's disease, six times more than the levels that have been reported by the Centers for Disease Control and Prevention (CDC).
Fortunately, thanks to your leadership several years ago, our nation has a National Plan to Address Alzheimer's Disease that established as goal one preventing and effectively treating the disease by 2025, a mere 10 years away. As your resolution recognizes, while we can set bold goals, we simply will not achieve them absent the appropriation of necessary resources. I commend you for being a champion in Congress behind measures to substantially increase the amount of public resources committed to Alzheimer's disease research so we can reach the level of $2 billion in annual funding that multiple experts have estimated as being needed to maximize our chances of achieving the 2025 goal.
I understand the multiple fiscal challenges confronting the nation. At the same time, we must recognize that the question is not whether or not we will pay for Alzheimer's. We are paying, dearly, today, and we will pay even more tomorrow unless we redouble efforts to achieve scientific breakthroughs and develop therapies and means of prevention. Your resolution outlines a sensible track to achieve the necessary level of funding within a timeframe during which we can achieve the necessary impact, and makes clear that preventing and treating Alzheimer's disease must be a national priority.
Thank you, again, for your tremendous leadership on behalf of all Americans impacted by this disease.
Sincerely, George Vradenburg, Founder and Chairman.
____ Alzheimer's Association, Washington, DC, February 11, 2015.
Hon. Susan Collins, U.S. Senate, Washington, DC.
Hon. Amy Klobuchar, U.S. Senate, Washington, DC.
Dear Senator Collins and Senator Klobuchar: On behalf of the Alzheimer's Association and its nationwide network of advocates, thank you for your continued leadership on issues and legislation important to Americans with Alzheimer's and their caregivers. The Alzheimer's Association proudly supports your most recent Alzheimer's resolution, which supports the goals of National Plan to Address Alzheimer's Disease.
The Alzheimers Association is the world's leading voluntary health organization in Alzheimers care, support and research. Our mission is to eliminate Alzheimer's disease and other dementias through the advancement of research; to provide and enhance care and support for all affected; and to reduce the risk of dementia through the promotion of brain health. Our vision is a world without Alzheimer's.
As one of our nation's strongest voices on behalf of Americans living with Alzheimer's, you know that more than 5 million Americans are living with the disease, and without significant action, as many as 16 million Americans will have Alzheimer's by 2050. A 2013 study funded by the National Institutes of Health (NIH) and published in the New England Journal of Medicine further confirmed that Alzheimers disease is the most expensive disease in America. Additionally, as the baby boomer generation ages, one in eight will develop Alzheimer's. This explosive growth will cause Alzheimers costs to Medicare and Medicaid to increase from $153 billion today to nearly $800 billion in 2050 (in today's dollars) and threatens to bankrupt families, businesses and our health care system. Unfortunately, our work is only growing more urgent.
The passage of the National Alzheimer's Project Act in 2010, and the subsequent release of the National Plan to Address Alzheimer's Disease, marks a new era for Alzheimers disease and other dementias. Achieving the first goal of the National Plan, to prevent and effectively treat Alzheimer's disease by 2025, and supporting individuals with the disease and their caregivers are critical to the success of this legislation.
The Alzheimers Association deeply appreciates your continued leadership on behalf of all American's living with Alzheimer's. If you have any questions about this or any other legislation, please contact Rachel Conant, Director of Federal Affairs, at email@example.com or at 202.638.7121.
Sincerely, Robert Egge, Executive Vice President, Government Affairs, Alzheimer's Association.
Ms. COLLINS. Mr. President, we have to face the facts that if we do not invest in Alzheimer's research at the levels the experts tell us is necessary to develop effective treatments for this disease or perhaps a means of prevention or eventually a cure, this disease is going to continue to cause untold suffering not only for its victims but for its families, and it will bankrupt America 's health care system.
I urge our colleagues to join us as cosponsors. I want, in particular, to recognize my partner in this effort, the Senator from Minnesota, Ms. Klobuchar. The home of the Mayo Clinic is in her State. She has been stalwart in supporting the efforts to increase funding for Alzheimer's research.
With that, I am very pleased to yield to my partner, Senator Klobuchar.
The PRESIDING OFFICER. The Senator from Minnesota.